美国食品药品监督管理局（FDA）已正式批准由Revolution Medicines生产的胰腺癌治疗药物daraxonrasib（商品名Rasonque）1。该药物通过锁定并关闭突变的KRAS基因来阻止癌症扩散，在涉及500名患者的临床试验中，使服药患者的平均生存时间从化疗组的6.6个月延长至13.2个月1。同时，服用daraxonrasib的患者中约有44%出现严重副作用，而化疗组这一比例为57.5%1。2025年，FDA授予该药物“突破性疗法”（Breakthrough Therapy）认定，并提前六个月批准了该药物1。
在美国，每年约有67000人被诊断出胰腺癌，且超过90%的胰腺肿瘤存在KRAS基因突变1。此外，前美国参议员本·萨斯（Ben Sasse）目前正在参加该药物的临床试验1。
The US Food and Drug Administration (FDA) has approved daraxonrasib, marketed under the brand name Rasonque, as a treatment for pancreatic cancer 1. Manufactured by Revolution Medicines, the drug works by locking and shutting down the mutated KRAS gene to prevent the spread of cancer 1. This mechanism is significant because over 90% of pancreatic tumors carry KRAS gene mutations 1. The FDA approved the drug six months ahead of schedule, following its decision in 2025 to grant the medication Breakthrough Therapy designation 1.
In a clinical trial involving 500 patients, those treated with daraxonrasib had an average survival time of 13.2 months, compared to 6.6 months in the chemotherapy group 1. Additionally, approximately 44% of patients taking daraxonrasib experienced severe side effects, compared to 57.5% in the chemotherapy group 1. About 67,000 people are diagnosed with pancreatic cancer in the US each year 1. Former US Senator Ben Sasse is currently participating in a clinical trial for the drug 1.
评论
还没有评论，欢迎留下第一条。